These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 24091594

  • 1. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
    Hadji P, Felsenberg D, Amling M, Hofbauer LC, Kandenwein JA, Kurth A.
    Osteoporos Int; 2014 Jan; 25(1):339-47. PubMed ID: 24091594
    [Abstract] [Full Text] [Related]

  • 2. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study.
    Cooper A, Drake J, Brankin E, PERSIST Investigators.
    Int J Clin Pract; 2006 Aug; 60(8):896-905. PubMed ID: 16800837
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
    Paggiosi MA, Peel N, McCloskey E, Walsh JS, Eastell R.
    Osteoporos Int; 2014 Dec; 25(12):2729-41. PubMed ID: 25074351
    [Abstract] [Full Text] [Related]

  • 4. Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.
    Sahota O, Narayanasamy M, Bastounis A, Paskins Z, Bishop S, Langley T, Gittoes N, Davis S, Baily A, Holmes M, Leonardi-Bee J.
    Health Technol Assess; 2024 Apr; 28(21):1-169. PubMed ID: 38634483
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 6. Comparative adherence to weekly oral and quarterly intravenous bisphosphonates among patients with limited heath literacy who sustained distal radius fractures.
    Roh YH, Noh JH, Gong HS, Baek GH.
    J Bone Miner Metab; 2018 Sep; 36(5):589-595. PubMed ID: 28983705
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P, Papaioannou N, Gielen E, Feudjo Tepie M, Zhang E, Frieling I, Geusens P, Makras P, Resch H, Möller G, Kalouche-Khalil L, Fahrleitner-Pammer A.
    Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
    Lee YH, Song GG.
    Korean J Intern Med; 2011 Sep; 26(3):340-7. PubMed ID: 22016595
    [Abstract] [Full Text] [Related]

  • 10. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.
    Kendler DL, McClung MR, Freemantle N, Lillestol M, Moffett AH, Borenstein J, Satram-Hoang S, Yang YC, Kaur P, Macarios D, Siddhanti S, DAPS Investigators.
    Osteoporos Int; 2011 Jun; 22(6):1725-35. PubMed ID: 20827547
    [Abstract] [Full Text] [Related]

  • 11. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
    Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL, DAPS Investigators.
    Osteoporos Int; 2012 Jan; 23(1):317-26. PubMed ID: 21927922
    [Abstract] [Full Text] [Related]

  • 12. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG.
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [Abstract] [Full Text] [Related]

  • 13. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M, Viapiana O, Gatti D, Adami S.
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [Abstract] [Full Text] [Related]

  • 14. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
    Miller PD, Epstein S, Sedarati F, Reginster JY.
    Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
    [Abstract] [Full Text] [Related]

  • 15. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.
    Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C.
    Osteoporos Int; 2010 Jan; 21(1):145-55. PubMed ID: 19459025
    [Abstract] [Full Text] [Related]

  • 16. Ibandronate: a review of its use in the management of postmenopausal osteoporosis.
    Frampton JE, Perry CM.
    Drugs; 2008 Jan; 68(18):2683-707. PubMed ID: 19093707
    [Abstract] [Full Text] [Related]

  • 17. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.
    Hadji P, Gamerdinger D, Spieler W, Kann PH, Loeffler H, Articus K, Möricke R, Ziller V.
    Osteoporos Int; 2012 Feb; 23(2):625-33. PubMed ID: 21442459
    [Abstract] [Full Text] [Related]

  • 18. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [Abstract] [Full Text] [Related]

  • 19. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
    Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2016 Jan; 27(1):21-31. PubMed ID: 25990354
    [Abstract] [Full Text] [Related]

  • 20. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
    Reginster JY.
    Curr Pharm Des; 2005 Jan; 11(28):3711-28. PubMed ID: 16305506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.